Literature DB >> 26687610

Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.

Peter Vandenberghe1, Iwona Wlodarska2, Thomas Tousseyn3, Luc Dehaspe2, Daan Dierickx4, Magali Verheecke5, Anne Uyttebroeck6, Oliver Bechter7, Michel Delforge4, Vincent Vandecaveye8, Nathalie Brison2, Gregor E G Verhoef4, Eric Legius2, Frederic Amant5, Joris R Vermeesch2.   

Abstract

BACKGROUND: Hodgkin's lymphoma is one of the most common lymphoid neoplasms in young adults, but the low abundance of neoplastic Hodgkin/Reed-Sternberg cells in the tumour hampers the elucidation of its pathogenesis, biology, and diversity. After an incidental observation that genomic aberrations known to occur in Hodgkin's lymphoma were detectable in circulating cell-free DNA, this study was undertaken to investigate whether circulating cell-free DNA can be informative about genomic imbalances in Hodgkin's lymphoma.
METHODS: We applied massive parallel sequencing to circulating cell-free DNA in a prospective study of patients with biopsy proven nodular sclerosis Hodgkin's lymphoma. Genomic imbalances in Hodgkin/Reed-Sternberg cells were investigated by fluorescence in-situ hybridisation (FISH) on tumour specimens.
FINDINGS: By non-invasive prenatal testing, we observed several genomic imbalances in circulating cell-free DNA of a pregnant woman, who was subsequently diagnosed with early-stage nodular sclerosis Hodgkin's lymphoma stage IIA during gestation. FISH on tumour tissue confirmed corresponding genomic imbalances in Hodgkin/Reed-Sternberg cells. We prospectively studied circulating cell-free DNA of nine nodular sclerosis Hodgkin's lymphoma cases: eight at first diagnosis and one at first relapse. Seven patients had stage IIA disease and two had stage IVB disease. In eight, genomic imbalances were detected, including, among others, gain of chromosomes 2p and 9p, known to occur in Hodgkin's lymphoma. These gains and losses in circulating cell-free DNA were extensively validated by FISH on Hodgkin/Reed-Sternberg cells in biopsy samples. Initiation of chemotherapy induced normalisation of circulating cell-free DNA profiles within 2-6 weeks. The cell cycle indicator Ki67 and cleaved caspase-3 were detected in Hodgkin/Reed-Sternberg cells by immunohistochemistry, suggesting high turnover of Hodgkin/Reed-Sternberg cells.
INTERPRETATION: In early and advanced stage nodular sclerosis Hodgkin's lymphoma, genomic imbalances in Hodgkin/Reed-Sternberg cells can be identified by massive parallel sequencing of circulating cell-free DNA at diagnosis. The rapid normalisation of circulating cell-free DNA profiles on therapy initiation suggests a potential role for circulating cell-free DNA profiling in early response monitoring. This finding creates several new possibilities for exploring the diversity of Hodgkin's lymphoma, and has potential implications for the future clinical development of biomarkers and precision therapy for this malignancy. FUNDING: KU Leuven-University of Leuven and University Hospitals Leuven.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26687610     DOI: 10.1016/S2352-3026(14)00039-8

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN: 2352-3026            Impact factor:   18.959


  37 in total

1.  Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.

Authors:  Elif Hindié; Charles Mesguich; Krimo Bouabdallah; Noël Milpied
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

Review 2.  Prenatal and pre-implantation genetic diagnosis.

Authors:  Joris Robert Vermeesch; Thierry Voet; Koenraad Devriendt
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

3.  Circulating cell-free DNA in hematological malignancies.

Authors:  Lieselot Buedts; Peter Vandenberghe
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

4.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.

Authors:  Vincent Camus; Aspasia Stamatoullas; Sylvain Mareschal; Pierre-Julien Viailly; Nasrin Sarafan-Vasseur; Elodie Bohers; Sydney Dubois; Jean Michel Picquenot; Philippe Ruminy; Catherine Maingonnat; Philippe Bertrand; Marie Cornic; Valérie Tallon-Simon; Stéphanie Becker; Liana Veresezan; Thierry Frebourg; Pierre Vera; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2016-06-13       Impact factor: 9.941

5.  Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.

Authors:  Joanna Przybyl; Jacob J Chabon; Lien Spans; Kristen N Ganjoo; Sujay Vennam; Aaron M Newman; Erna Forgó; Sushama Varma; Shirley Zhu; Maria Debiec-Rychter; Ash A Alizadeh; Maximilian Diehn; Matt van de Rijn
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

Review 6.  The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders.

Authors:  Jennifer Crombie; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

Review 7.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

Review 8.  Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

Authors:  Alex F Herrera; Philippe Armand
Journal:  J Clin Oncol       Date:  2017-09-21       Impact factor: 44.544

Review 9.  High-throughput sequencing for noninvasive disease detection in hematologic malignancies.

Authors:  Florian Scherer; David M Kurtz; Maximilian Diehn; Ash A Alizadeh
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

Review 10.  The value of cell-free DNA for molecular pathology.

Authors:  Caitlin M Stewart; Prachi D Kothari; Florent Mouliere; Richard Mair; Saira Somnay; Ryma Benayed; Ahmet Zehir; Britta Weigelt; Sarah-Jane Dawson; Maria E Arcila; Michael F Berger; Dana Wy Tsui
Journal:  J Pathol       Date:  2018-03-12       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.